Abstract | BACKGROUND & AIMS: METHODS: RESULTS:
Adiponectin levels increased from 3.7 to 10.3 mug/mL at week 48 (P < .01); the levels of the other cytokines were unchanged: TNF-alpha, 9.1 vs 8.8 pg/mL; IL-1a, 3.9 vs 3.4 pg/mL; IL-6, 19.4 vs 13.4 pg/mL; and leptin, 24.8 vs 29.6 ng/mL (P > .05 for all). Pioglitazone therapy was associated with improvements in steatosis (2.5 vs 1.0), parenchymal inflammation (3.3 vs 2.1), cell injury (2.2 vs 0.9), and fibrosis (2.0 vs 1.4). The change in adiponectin level was associated with the improvement in steatosis (P = .03) as well as in a summary NASH activity index score (P = .01). Changes in IL-1, IL-6, TNF-alpha, and leptin levels did not correlate with improvements in the histological features. CONCLUSIONS:
|
Authors | Glen Lutchman, Kittichai Promrat, David E Kleiner, Theo Heller, Marc G Ghany, Jack A Yanovski, T Jake Liang, Jay H Hoofnagle |
Journal | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
(Clin Gastroenterol Hepatol)
Vol. 4
Issue 8
Pg. 1048-52
(Aug 2006)
ISSN: 1542-3565 [Print] United States |
PMID | 16814613
(Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Intramural)
|
Chemical References |
- Adiponectin
- Cytokines
- Hypoglycemic Agents
- Leptin
- Thiazolidinediones
- Pioglitazone
|
Topics |
- Adiponectin
(blood)
- Adult
- Biopsy
- Cytokines
(blood)
- Fatty Liver
(blood, drug therapy, pathology)
- Female
- Humans
- Hypoglycemic Agents
(therapeutic use)
- Leptin
(blood)
- Liver
(pathology)
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Pilot Projects
- Pioglitazone
- Thiazolidinediones
(therapeutic use)
|